Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus

Abstract

This study provides evidence that cancer incidence in the first few years after starting metformin or sulphonylurea therapy in type 2 diabetes patients is not much affected by choice of hypoglycaemic drug class.